CVS Health Corporation operates an integrated health care model that combines retail pharmacy, pharmacy benefit management, health insurance, medical clinics, specialty and mail pharmacy support, and related consumer health services. Recurring company news includes quarterly results and guidance, segment performance across Health Services, Health Care Benefits, and Pharmacy & Consumer Wellness, and capital returns through common-stock dividends.
Updates also cover CVS Caremark formulary decisions, biosimilar adoption, Aetna prior authorization and plan-administration initiatives, community health investments by the CVS Health Foundation, and developments involving Omnicare, the company's long-term care pharmacy subsidiary.
CVS Health (NYSE: CVS) announced that Teresa Heitsenrether, Chief Data & Analytics Officer at JPMorgan Chase and member of its Operating Committee, will join its Board of Directors effective November 18, 2026. She brings nearly forty years of financial services leadership, with expertise in data, analytics, artificial intelligence and operational transformation.
Larry Robbins, a director since 2024 who served on the Audit and Public Policy and External Affairs Committees, departed the Board effective August 13, 2026. According to CVS Health, Robbins played a key role in sharpening the company’s financial and operational focus during a period of transition.
CVS Health (NYSE: CVS), through its CVS Caremark pharmacy benefit manager, released findings from The State of Pharmacy Management Survey conducted with Employee Benefit News. Employers cited high drug prices, GLP-1 coverage and specialty medications as top concerns, and view PBMs as key partners in cost control and access.
According to CVS Caremark, only 49% of employers currently encourage biosimilar substitution and 12% educate employees, despite biosimilars’ cost-saving potential. CVS Caremark reports more than $3.3 billion in gross Humira-related savings since April 2024 and, as of July 1, 2026, has preferred Stelara biosimilars Pyzchiva and Yesintek on common commercial formularies, often at $0 member cost.
The company highlights GLP-1 weight management strategies, noting clients using its CVS Weight Management program spent up to 26% less on GLP-1 weight-loss drugs. CVS Caremark also invests over $770 million annually in technology and promotes its TrueCost pricing model to improve transparency and predictability for plan sponsors.
CVS Health (NYSE: CVS) reported second quarter 2026 revenues of $106.1 billion, up 7.3% year-over-year, with GAAP diluted EPS of $2.31 (vs. $0.80) and adjusted EPS of $2.58 (vs. $1.81). Operating income rose to $4.7 billion and adjusted operating income to $5.2 billion, driven by gains across all segments and the absence of prior-year litigation charges.
Year-to-date cash flow from operations reached $10.6 billion, and CVS raised 2026 guidance: GAAP EPS to $6.84–$7.04, adjusted EPS to $7.90–$8.10, and cash flow from operations to at least $11.5 billion. Health Care Benefits adjusted operating income increased 85.5% with the medical benefit ratio improving 250 bps; Health Services revenues grew 11.5%; Pharmacy & Consumer Wellness adjusted operating income rose 10.2%, aided by Rite Aid asset acquisitions. CVS also highlighted GLP-1 support initiatives and deployment of agentic AI tools in claims and call centers.
CVS Health (NYSE: CVS) announced an expanded direct-to-consumer weight management offering centered on GLP-1 medications, combining digital care and in-store support. CVS Pharmacy now offers all FDA-approved GLP-1s, including injectable and oral options, with access via insurance and cash-pay pathways.
A new collaboration with Eli Lilly will let eligible Zepbound and Foundayo patients see transparent, reimbursed and self-pay pricing in the CVS Health app for potential same-day pickup at about 9,000 CVS Pharmacy locations by early Q4 2026. CVS also introduced a $29 MinuteClinic digital weight loss visit, with no membership or recurring fee, available 24/7 to connect eligible adults with licensed clinicians who may prescribe GLP-1 therapy and provide follow-up care.
CVS Health (NYSE: CVS) reported that its AI Learning Academy earned two Gold and one Silver honors at the 11th Annual Stevie Awards for Great Employers, recognizing employee development, training and workplace culture.
The Academy won Gold for Employee Upskill/Reskill Training and AI Workforce Innovation Team of the Year, and Silver for AI in Learning and Skills Development Achievement. Launched in February 2026, the program uses a phased, persona-based model to build practical AI capabilities. It generated more than 18,500 live session attendances, up to a 72% improvement in colleague confidence using AI, and 45–60 minutes of reported weekly productivity gains for up to 90% of participants after 30 days. CVS Health also highlighted earlier 2026 Stevie wins for enterprise-scale AI in predictive modeling, clinical authorization, claims orchestration and customer experience.
CVS Health (NYSE: CVS) reported it was named Overall Winner and received four gold awards at the 2026 US Customer Experience Awards, recognizing Best Use of AI, Best Measurement in CX, Best Employee Engagement, and Customers at the Heart of Everything for its consumer-centric, data-driven CX ecosystem.
CVS Health (NYSE:CVS) announced that its subsidiary Health100 has earned the CARIN Code of Conduct for Consumer-Facing Applications Accreditation from DirectTrust for the Health100 mobile app. The independent review assessed compliance with the CARIN Alliance Code of Conduct, including transparency, consent, data use and disclosure, individual access, security, provenance, accountability and education for stakeholders.
According to CVS Health, the accreditation validates Health100’s approach to consumer-directed data sharing, privacy and security as it connects consumers, health plans, PBMs, pharmacies, providers, employers and digital health solutions in a unified experience and supports cost transparency, care navigation and chronic condition management.
CVS Health (NYSE: CVS) reported expanding community health investments across Massachusetts, focused on affordable housing, nonprofit partnerships and free health services. According to CVS Health, the company has invested more than $83 million in affordable housing, helping create, preserve or renovate over 3,517 affordable units in cities including Worcester, Boston’s Jamaica Plain, Salem, Attleboro and Foxborough.
Recent projects include a $10 million investment in the former Worcester Boys Club, creating 80 affordable units for older adults, and over $16 million for transforming Blessed Sacrament in Jamaica Plain into 55 affordable family homes and a community arts and youth space. CVS Health also supports medically tailored meals through Community Servings and funds preventive care via Project Health® screenings and the DREAMH postpartum mobile care program with Mass General Brigham.
CVS Health (NYSE: CVS) announced that common prescription medications for dogs and cats are now available at approximately 9,000 CVS Pharmacy locations nationwide as of July 21, 2026. Pet owners can fill select pet-only prescriptions, such as antibiotics, allergy treatments, flea and tick control, insulin, and pain relievers, at local CVS Pharmacy stores, with options for in-store pickup or delivery where eligible.
According to CVS Health, pet prescriptions can use many of the same pharmacy services as human prescriptions, including automatic refills and prescription syncing, and can be managed via CVS.com profiles and the CVS Health app. The company also highlighted its in-store and online Pet section, including its Pet Central brand and national pet product brands.
CVS Health (NYSE: CVS) announced the opening of its first pharmacy-focused CVS Pharmacy location in Houston, at 8503A Gulf Freeway, as part of a plan to open nearly 20 such sites nationwide. These neighborhood pharmacies, averaging about 3,000 square feet, feature full-service prescription dispensing and a curated range of over-the-counter products.
According to CVS Health, the new format is designed to expand access to in-person pharmacy care, complementing existing traditional stores, store-in-store pharmacies, MinuteClinic locations, and Oak Street Health co-located centers. The company has already opened pharmacy-focused sites in Birmingham, Chicago, Detroit, and Washington, D.C., and plans two more in greater Houston plus over 40 additional CVS Pharmacy locations, including traditional stores and pharmacies in Target. CVS highlights survey data showing 80% of patients prefer face-to-face pharmacy care and 97% of pharmacy professionals view in-person interactions as vital.